Barrington Research Downgrades Haemonetics Corporation to Market Perform

Brokerage firm Barrington Research Downgrades its rating on Haemonetics Corporation(NYSE:HAE). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Barrington Research was issued on Aug 3, 2016.

In a different note, On Aug 2, 2016, Jefferies said it Maintains its rating on Haemonetics Corporation. In the research note, the firm Raises the price-target to $32.00 per share. The shares have been rated ‘Buy’ by the firm. On May 16, 2016, Goldman Sachs said it Upgrades its rating on Haemonetics Corporation. In the research note, the firm Raises the price-target to $25.00 per share. The shares have been rated ‘Neutral’ by the firm.

Haemonetics Corporation (HAE) made into the market gainers list on Fridays trading session with the shares advancing 0.72% or 0.26 points. Due to strong positive momentum, the stock ended at $36.25, which is also near the day’s high of $36.33. The stock began the session at $36.03 and the volume stood at 2,24,201 shares. The 52-week high of the shares is $39.785 and the 52 week low is $25.98. The company has a current market capitalization of $1,860 M and it has 5,12,97,382 shares in outstanding.

Haemonetics Corporation(HAE) last announced its earnings results on Aug 1, 2016 for Fiscal Year 2017 and Q1.Company reported revenue of $209.96M. Analysts had an estimated revenue of $205.24M. Earnings per share were $0.25. Analysts had estimated an EPS of $0.29.

Several Insider Transactions has been reported to the SEC. On Oct 28, 2015, Sandra Jesse (EVP and Chief Legal Officer) sold 778 shares at $32.13 per share price.Also, On Oct 28, 2015, Byron Selman (President, Global Markets) sold 344 shares at $32.13 per share price.On Oct 28, 2015, Jonathan White (Chief Science and Technology) sold 319 shares at $32.13 per share price, according to the Form-4 filing with the securities and exchange commission.

Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Haemonetics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Haemonetics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.